文献速递肿瘤 PET/CT神经核医学

18F-FDG PET在原发中枢神经系统淋巴瘤中的预后价值:评估中期代谢反应以改善患者分层

Prognostic Value of 18 F-FDG PET in Primary Central Nervous System Lymphoma : Assessing Interim Metabolic Response for Improving Patient Stratification.
PubMed 文献 · Clin Nucl Med · 2025-02-17

前瞻性纳入53例接受大剂量甲氨蝶呤方案治疗的原发中枢神经系统淋巴瘤患者,在诊断时和诱导化疗后行脑FDG PET,评估中期代谢参数。多因素分析显示中期hTNRmax高是预后不良的独立预测因子,低hTNRmax(≤1.0)患者中位无进展生存期显著长于高hTNRmax(>1.0)患者(25.0 vs 3.6个月,P<0.001);结合中期MRI临床反应评估与hTNRmax可将部分缓解亚组分类为预后显著不同的组(P<0.001)。中期hTNRmax高也是总生存期不良的独立预测因子(HR 2.76,95%CI 1.39-5.48,P=0.004)。

要点

  • 中期脑FDG PET的hTNRmax高是PCNSL无进展生存期不良的独立预测因子(HR 9.76,95%CI 1.90-50.11,P=0.01)。
  • 中期hTNRmax≤1.0患者中位无进展生存期显著长于>1.0患者(25.0 vs 3.6个月,P<0.001)。
  • 中期hTNRmax高也是总生存期不良的独立预测因子(HR 2.76,95%CI 1.39-5.48,P=0.004)。

核心结论

  • 中期脑FDG PET测量的hTNRmax是PCNSL的重要预后标志物。
  • 中期FDG PET评估有望改进疗效评估并指导个体化治疗策略。

研究设计与样本

  • 前瞻性研究纳入53例接受大剂量甲氨蝶呤方案治疗的PCNSL患者。
  • 在诊断时(基线PET)和诱导化疗后(中期PET)行脑FDG PET,评估中期PET参数包括hSUVmax、sumSUVmax、hTNRmax、sumTNRmax、hMTV和sumMTV。

主要发现

  • 多因素分析显示中期hTNRmax高是无进展生存期不良的独立显著预测因子(HR 9.76,95%CI 1.90-50.11,P=0.01)。
  • 中期hTNRmax低(≤1.0)患者中位无进展生存期显著长于中期hTNRmax高(>1.0)患者(25.0 vs 3.6个月,P<0.001)。
  • 结合中期MRI临床反应评估与hTNRmax可将部分缓解亚组分类为预后显著不同的组(P<0.001)。
  • 多因素分析显示中期hTNRmax高是总生存期不良的独立显著预测因子(HR 2.76,95%CI 1.39-5.48,P=0.004)。

关键数值与推荐

  • 中期hTNRmax>1.0为高值,≤1.0为低值。
  • 中期hTNRmax高预测无进展生存期不良的HR为9.76(95%CI 1.90-50.11,P=0.01)。
  • 中期hTNRmax高预测总生存期不良的HR为2.76(95%CI 1.39-5.48,P=0.004)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE OF THE REPORT: The usefulness of brain 18 F-FDG PET/CT in primary central nervous system lymphoma (PCNSL) remains underexplored. This study investigated whether early metabolic responses in interim brain FDG PET/CT serve as a prognostic indicator of PCNSL treatment outcomes. PATIENTS AND METHODS: This prospective study included 53 patients with PCNSL who underwent a high-dose methotrexate-based treatment. Brain FDG PET was performed at diagnosis (baseline PET) and after induction chemotherapy (interim PET), assessing interim PET parameters such as the highest maximum standardized uptake value (hSUV max ), sum of SUV max (sumSUV max ), highest tumor-to-normal ratio (hTNR max ), sum of TNR max (sumTNR max ), highest metabolic tumor volume (MTV) (hMTV), and sum of MTV (sumMTV) across all PET-positive lesions. RESULTS: High interim hTNR max (hazards ratio: 9.76, 95% confidence interval: 1.90-50.11, P = 0.01) was an independently significant predictor of poor progression-free survival in multivariate analysis. Patients with low interim hTNR max (≤1.0) had a significantly longer median progression-free survival than those with high interim hTNR max (>1.0) (25.0 vs 3.6 months, P < 0.001). Incorporating interim MRI-based clinical response assessments and hTNR max allowed the classification of partial response subgroups with markedly different prognoses ( P < 0.001). High interim hTNR max (hazards ratio: 2.76, 95% confidence interval: 1.39-5.48, P = 0.004) was an independently significant predictor of poor overall survival in multivariate analysis. CONCLUSIONS: The hTNR max measurement from interim brain FDG PET scans emerges as an important prognostic marker in PCNSL. These findings underscore the potential of interim FDG PET evaluations to refine response assessments and inform tailored therapeutic strategies.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Song GY, Jang HC, Kim M, et al. Prognostic Value of 18 F-FDG PET in Primary Central Nervous System Lymphoma : Assessing Interim Metabolic Response for Improving Patient Stratification. Clin Nucl Med. 2025. PMID: 39957068. doi:10.1097/RLU.0000000000005703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。